Dobutamin Hameln (Dobutamine)
Intravenous inotropic agent for acute heart failure and hemodynamic support
Dobutamin Hameln is a synthetic catecholamine administered by continuous intravenous infusion to strengthen the heart's pumping action. It is primarily used in hospital settings to treat acute heart failure, cardiogenic shock, and post-cardiac surgery low output states. The medication works by stimulating beta-1 adrenergic receptors in the heart, increasing cardiac contractility and improving blood flow throughout the body.
Quick Facts
Key Takeaways
- Dobutamine is a hospital-only inotropic agent that increases the heart's pumping strength in acute heart failure and cardiogenic shock.
- It must be administered as a continuous intravenous infusion by trained healthcare professionals with full hemodynamic monitoring.
- The most common side effects include increased heart rate, chest pain, and cardiac arrhythmias — all requiring continuous monitoring.
- Tolerance may develop after 72 hours of continuous infusion, potentially requiring dose adjustments.
- Approved for all pediatric age groups (neonates to 18 years) with careful dose titration and monitoring.
What Is Dobutamin Hameln and What Is It Used For?
Dobutamin Hameln belongs to the pharmacological group of catecholamines — substances that stimulate specific receptors in the cardiovascular system. Unlike naturally occurring catecholamines such as adrenaline and noradrenaline, dobutamine is a synthetic compound specifically designed to have a preferential effect on the heart's contractile force while minimizing unwanted effects on blood pressure and heart rate.
The primary mechanism of action involves stimulation of beta-1 adrenergic receptors located on cardiac muscle cells. When dobutamine binds to these receptors, it triggers a cascade of intracellular events that increase the force of each heartbeat (positive inotropic effect). This results in a greater volume of blood being ejected from the heart with each contraction, thereby improving overall cardiac output and oxygen delivery to vital organs. Dobutamine also has mild beta-2 adrenergic effects that cause relaxation of blood vessels (vasodilation), which can reduce the workload on the heart by decreasing the resistance against which it must pump.
Dobutamin Hameln is indicated for the following clinical situations:
- Acute decompensated heart failure — when the heart cannot maintain adequate blood flow to meet the body's metabolic demands, and conventional treatments are insufficient.
- Cardiogenic shock with severe hypotension — a life-threatening condition where the heart fails so severely that blood pressure drops dangerously low, threatening organ perfusion.
- Post-cardiac surgery support — to provide temporary hemodynamic support after heart operations when the myocardium is stunned or weakened.
- Dobutamine stress echocardiography — a diagnostic procedure in which dobutamine is infused at increasing doses to simulate exercise and detect areas of poor blood supply to the heart muscle (myocardial ischemia).
Use in Children
Dobutamine is approved for use in all pediatric age groups, from neonates through to adolescents aged 18 years. In children, it serves as inotropic support for conditions characterized by reduced cardiac output with organ hypoperfusion. These conditions include decompensated heart failure, post-cardiac surgery recovery, cardiomyopathy (disease of the heart muscle), and cardiogenic or septic shock. Pediatric use requires particularly careful dose titration and monitoring due to the narrower therapeutic window observed in children compared to adults.
The European Society of Cardiology (ESC) and the American Heart Association (AHA) both recognize dobutamine as a first-line inotropic agent for short-term hemodynamic support in acute heart failure. The World Health Organization (WHO) includes dobutamine on its Model List of Essential Medicines, underscoring its critical role in emergency and intensive care medicine worldwide.
What Should You Know Before Receiving Dobutamin Hameln?
Contraindications
Dobutamin Hameln must not be given if any of the following conditions apply:
- Allergic to dobutamine or any excipient — An allergic reaction may include skin rash, itching, difficulty breathing, or swelling of the face, lips, throat, or tongue.
- Mechanical obstruction of the heart or blood vessels — Conditions such as hypertrophic obstructive cardiomyopathy, severe aortic stenosis, or cardiac tamponade, which prevent the heart from filling or ejecting blood properly.
- Hypovolemia (insufficient circulating blood volume) — Blood volume must be adequately restored before dobutamine is administered.
- Pheochromocytoma — A catecholamine-secreting tumor near the kidney that causes uncontrolled high blood pressure.
For the specific indication of dobutamine stress echocardiography, additional contraindications apply. These include recent myocardial infarction (within 10 days), unstable angina, significant left main coronary artery disease, hemodynamically significant aortic stenosis, complex cardiac arrhythmias, severe arterial hypertension, and obstructive cardiomyopathy. The physician performing the procedure is responsible for assessing these contraindications prior to testing.
Warnings and Precautions
Discuss your complete medical history with your physician before receiving dobutamine. Special caution is required in the following circumstances:
- Asthma with sulfite sensitivity — Dobutamin Hameln contains sodium metabisulfite (E223), which can cause severe hypersensitivity reactions and bronchospasm in susceptible individuals, particularly those with asthma.
- Severe coronary artery disease — Dobutamine increases myocardial oxygen demand, which may worsen ischemia in patients with significant coronary stenosis.
- Acute (sudden) heart failure — The underlying cause should be identified and treated concurrently with dobutamine administration.
- Atrial fibrillation — Dobutamine can increase ventricular rate in patients with uncontrolled atrial fibrillation; consider rate control with digoxin before starting dobutamine.
Increased heart rate and elevated blood pressure appear to be more frequent and intense in children compared to adults. The neonatal cardiovascular system has been reported to be less responsive to dobutamine, and hypotensive effects are observed more frequently in adults than in young children. High doses should be used with particular caution in pediatric patients, and the required dose should be carefully titrated by the treating physician.
Pregnancy and Breastfeeding
Dobutamin Hameln should not be administered to pregnant women unless the clinical benefit clearly justifies the potential risk to the fetus. There is limited data on the use of dobutamine during human pregnancy, and animal reproduction studies are insufficient to determine safety. If dobutamine must be used during pregnancy, the lowest effective dose should be employed for the shortest possible duration.
It is not known whether dobutamine is excreted in human breast milk. Women who are breastfeeding are advised to discontinue breastfeeding during treatment with Dobutamin Hameln. Given the short half-life of dobutamine (approximately 2 minutes), breastfeeding can typically be resumed shortly after the infusion is discontinued, following consultation with the treating physician.
Sodium Metabisulfite Content
Dobutamin Hameln contains sodium metabisulfite (E223), which may rarely cause severe hypersensitivity reactions including bronchospasm, particularly in patients with a history of asthma or sulfite allergy. The product contains less than 1 mmol (23 mg) sodium per 20 ml ampoule, making it essentially "sodium-free." This is relevant for patients on a controlled sodium diet.
How Does Dobutamin Hameln Interact with Other Drugs?
Because dobutamine is always administered in a monitored clinical setting, drug interactions are managed by the healthcare team in real time. However, understanding potential interactions is important for comprehensive patient safety. The following medications have been identified as interacting with dobutamine:
| Drug / Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Beta-blockers (e.g., metoprolol, propranolol) | Antagonism — beta-blockers oppose the cardiac effects of dobutamine | Major — may negate the therapeutic inotropic effect |
| Inhalational anesthetics (e.g., halothane, isoflurane) | Increased risk of ventricular arrhythmias due to myocardial sensitization | Major — requires close cardiac rhythm monitoring |
| Dopamine | Additive inotropic and chronotropic effects | Moderate — combined use may increase heart rate excessively |
| Entacapone (Parkinson's medication) | COMT inhibition potentiates catecholamine effects | Moderate — enhanced cardiovascular response |
| Alpha-blockers (e.g., doxazosin) | May enhance vasodilatory effects | Moderate — risk of excessive hypotension |
| ACE inhibitors (e.g., enalapril) | Additive hypotensive effects | Moderate — blood pressure monitoring required |
| Vasodilators (e.g., nitroprusside, nitroglycerin) | Synergistic vasodilation and afterload reduction | Moderate — commonly used together under close monitoring |
| Antidiabetic agents (insulin, oral hypoglycemics) | Catecholamines can increase blood glucose levels | Minor — blood glucose monitoring recommended |
Incompatibilities
Dobutamine and sodium metabisulfite are chemically incompatible with many pharmaceutical compounds. The medication must not be mixed with sodium bicarbonate or other strongly alkaline solutions, as alkaline pH causes rapid degradation of dobutamine. In general, Dobutamin Hameln should not be mixed with other drugs in the same infusion line unless compatibility has been confirmed. Compatible diluents include 5% glucose solution, 0.9% sodium chloride solution, and 0.45% sodium chloride in 5% glucose solution.
What Is the Correct Dosage of Dobutamin Hameln?
Dobutamine doses must be individually tailored. The required infusion rate depends on the patient's hemodynamic response and any side effects observed. Dobutamin Hameln (12.5 mg/ml concentrate) must be diluted before administration and is given exclusively as a continuous intravenous infusion. Only trained healthcare professionals in settings with emergency equipment should administer this medication.
Adults
Standard Adult Dosing
The majority of adult patients respond to infusion rates of 2.5 to 10 micrograms/kg/minute. In exceptional cases, doses up to 40 micrograms/kg/minute have been used. The infusion should be started at the low end of the dosing range and titrated upward based on hemodynamic parameters including cardiac output, blood pressure, heart rate, and urine output.
| Dose Range | 50 kg Patient | 70 kg Patient | 90 kg Patient |
|---|---|---|---|
| Low (2.5 µg/kg/min) | 15 ml/h (5 drops/min) | 21 ml/h (7 drops/min) | 27 ml/h (9 drops/min) |
| Medium (5 µg/kg/min) | 30 ml/h (10 drops/min) | 42 ml/h (14 drops/min) | 54 ml/h (18 drops/min) |
| High (10 µg/kg/min) | 60 ml/h (20 drops/min) | 84 ml/h (28 drops/min) | 108 ml/h (36 drops/min) |
For double concentration solutions (500 mg dobutamine in 500 ml, or 250 mg in 250 ml), the infusion rate must be halved. For infusion pump preparations (250 mg in 50 ml, giving 5 mg/ml), significantly lower volume rates are used.
Children (Neonates to 18 Years)
Pediatric Dosing
A starting dose of 5 micrograms/kg/minute is recommended for all pediatric age groups. The dose is adjusted according to clinical response within the range of 2 to 20 micrograms/kg/minute. Some patients may respond to doses as low as 0.5–1.0 micrograms/kg/minute.
There is reason to believe that the minimum effective dose in children is higher than in adults. However, the maximum tolerated dose in children may be lower than in adults. Most side effects (particularly tachycardia) are observed at doses of 7.5 micrograms/kg/minute or higher. The dose must be carefully titrated with awareness of the presumed narrower therapeutic window in pediatric patients.
For neonatal intensive care, the recommended preparation involves diluting 30 mg per kg of body weight to a final volume of 50 ml of infusion fluid. An intravenous infusion rate of 0.5 ml/hour then delivers a dose of 5 micrograms/kg/minute. Solutions with higher concentrations should only be infused through a central venous catheter.
Dobutamine Stress Echocardiography (Adults Only)
For diagnostic stress testing, dobutamine is administered using a graduated dosing protocol. The most commonly used regimen begins at 5 micrograms/kg/minute and increases every 3 minutes to 10, 20, 30, and then 40 micrograms/kg/minute until diagnostic endpoints are reached. If adequate diagnostic information is not obtained, atropine sulfate (0.5 to 2 mg in divided doses of 0.25–0.5 mg at 1-minute intervals) may be added to increase heart rate, or the dobutamine infusion rate may be increased to 50 micrograms/kg/minute.
Stress echocardiography with dobutamine must only be performed by physicians with sufficient experience in pharmacological stress testing. Continuous echocardiographic monitoring of all myocardial wall segments, ECG monitoring, and blood pressure measurement are mandatory. Emergency equipment including a defibrillator, intravenous beta-blockers, and nitrates must be immediately available, and resuscitation-trained personnel must be present throughout the procedure.
Important Administration Notes
- Gradual discontinuation: The dose of dobutamine must be reduced gradually before stopping treatment. Abrupt discontinuation may cause hemodynamic deterioration.
- Tolerance: If dobutamine is administered continuously for more than 72 hours, tolerance may develop, necessitating dose increases to maintain the same hemodynamic effect.
- Monitoring: During dobutamine administration, heart rate, cardiac rhythm, blood pressure, urine output, and infusion rate must be continuously monitored. Cardiac output, central venous pressure (CVP), and pulmonary capillary wedge pressure (PCWP) should be monitored when possible.
- Duration: The infusion duration should be as short as clinically necessary, as determined by the treating physician.
What Are the Side Effects of Dobutamin Hameln?
Like all medicines, dobutamine can cause side effects, although not everyone experiences them. Because dobutamine is administered in a monitored clinical environment, side effects can be detected and managed promptly. Most side effects are dose-related and resolve quickly when the infusion rate is reduced or the infusion is stopped.
Very Common
- Increased heart rate (tachycardia)
- Chest pain (angina pectoris)
- Cardiac rhythm disturbances (arrhythmias)
- Abnormal ECG findings (ST-segment elevation) during dobutamine stress testing
Common
- Blood pressure increase or decrease
- Vasoconstriction (narrowing of blood vessels)
- Palpitations (irregular heartbeat sensation)
- Ventricular tachycardia (rapid heartbeat originating in the ventricles)
- Headache
- Bronchospasm / asthma-like symptoms
- Shortness of breath (dyspnea)
- Increased white blood cell count (eosinophilia)
- Impaired blood clotting (platelet inhibition)
- Increased urinary frequency (at high doses)
- Nausea
- Skin rash (exanthema)
- Fever
- Inflammation at the injection site (phlebitis)
- Allergic (hypersensitivity) reactions including skin rash
- Eosinophilic myocarditis (inflammation of the heart muscle)
Uncommon
- Ventricular tachycardia (sustained uncontrolled ventricular contractions)
- Myocardial infarction (heart attack)
- Atrial fibrillation
- Left ventricular outflow tract obstruction during stress testing
- Severe anaphylactic reactions, potentially related to sodium metabisulfite sensitivity
- Severe life-threatening asthma episodes
Very Rare
- Bradycardia (abnormally slow heart rate)
- Myocardial ischemia (insufficient blood supply to the heart)
- Hypokalemia (low potassium levels)
- Petechiae (pinpoint bleeding spots on the skin)
- Heart block
- Coronary artery spasm (vasospasm)
- Skin necrosis (tissue death)
- Myoclonus (muscle spasms) in patients with severe renal failure
- Fatal cardiac rupture during dobutamine stress testing
Frequency Not Known
- Stress-induced cardiomyopathy (Takotsubo syndrome) — presenting as chest pain, shortness of breath, dizziness, fainting, and irregular heartbeat during stress echocardiography
- Heart failure (decreased pulmonary capillary wedge pressure)
- Restlessness and anxiety
- Paresthesia (tingling and numbness)
- Tremor (involuntary muscle twitching)
- Sensation of warmth
- Muscle cramps
Most cardiovascular side effects of dobutamine are dose-dependent and resolve rapidly when the infusion rate is reduced or the infusion is discontinued. Because of the drug's very short half-life (approximately 2 minutes), effects typically subside within minutes of dose reduction. Your medical team will continuously monitor your vital signs throughout the infusion and adjust the dosage as needed.
How Should Dobutamin Hameln Be Stored?
Dobutamin Hameln is stored and handled by healthcare professionals within the hospital pharmacy and clinical setting. The following storage requirements ensure the product remains safe and effective:
- Keep out of the sight and reach of children.
- No special temperature storage requirements — store at controlled room temperature.
- Store ampoules in the outer carton to protect from light, as dobutamine is light-sensitive.
- Do not freeze.
- Do not use if the solution appears cloudy, contains particles, or if the container is damaged.
- Do not use after the expiry date printed on the outer carton and ampoule (after "EXP"). The expiry date refers to the last day of the stated month.
After dilution: Chemical and physical stability has been demonstrated for 24 hours at 25°C. From a microbiological perspective, the product should be used immediately after dilution unless the method of preparation excludes the risk of microbial contamination. If not used immediately, storage times and conditions are the responsibility of the user. Infusion solutions should be prepared immediately before use.
What Does Dobutamin Hameln Contain?
Understanding the complete composition of Dobutamin Hameln is important for identifying potential allergens and ensuring compatibility with other medications:
Active Substance
The active ingredient is dobutamine, present as dobutamine hydrochloride. Each milliliter of solution contains 12.5 mg of dobutamine. Each 20 ml ampoule therefore contains a total of 250 mg dobutamine.
Excipients (Inactive Ingredients)
- Sodium metabisulfite (E223) — an antioxidant preservative. May cause hypersensitivity reactions in susceptible individuals, particularly those with asthma.
- Hydrochloric acid — used for pH adjustment to maintain solution stability.
- Water for injections — pharmaceutical-grade purified water as the solvent.
Appearance and Packaging
Dobutamin Hameln is a clear, colorless to slightly yellow concentrate for solution for infusion. It is supplied in 20 ml transparent glass ampoules. The product is available in original packs containing 1, 5, 10, or 50 ampoules. Not all pack sizes may be marketed in every country.
The marketing authorization holder and manufacturer is hameln pharma gmbh, Inselstrasse 1, 31787 Hameln, Germany. Manufacturing is carried out by Siegfried Hameln GmbH, Langes Feld 13, 31789 Hameln, Germany.
Frequently Asked Questions About Dobutamin Hameln
Dobutamine and dopamine are both catecholamines used in critical care, but they have different receptor profiles and clinical effects. Dobutamine primarily acts on beta-1 receptors, making it a stronger inotrope (increases heart contractility) with less effect on heart rate and blood pressure. Dopamine acts on dopaminergic, beta-1, and alpha-1 receptors in a dose-dependent manner, meaning its effects vary significantly with the dose used. At low doses, dopamine increases renal blood flow; at moderate doses, it increases cardiac output; and at high doses, it causes vasoconstriction. The choice between them depends on the specific clinical situation and the patient's hemodynamic profile.
Dobutamine is typically administered only in hospital settings — intensive care units, cardiac care units, or emergency departments — where continuous monitoring equipment and emergency resuscitation facilities are available. In some countries, continuous dobutamine infusion at home has been used as palliative therapy for end-stage heart failure patients who are not candidates for heart transplantation or mechanical circulatory support. However, home dobutamine therapy remains controversial and is associated with increased mortality risk in some studies. Any such use requires careful patient selection, family education, and regular follow-up by the cardiology team.
Dobutamine has a rapid onset of action. Hemodynamic effects typically begin within 1 to 2 minutes of starting the intravenous infusion, with peak effects reached within approximately 10 minutes. The drug's plasma half-life is very short, approximately 2 minutes, which means that effects also dissipate quickly when the infusion is reduced or stopped. This rapid on/off profile makes dobutamine highly controllable and allows the medical team to fine-tune the hemodynamic response in real time.
Continuous monitoring during dobutamine infusion includes: heart rate and cardiac rhythm (continuous ECG), arterial blood pressure (ideally via arterial line), urine output (hourly), and infusion rate. When feasible, additional monitoring should include cardiac output measurement, central venous pressure (CVP), and pulmonary capillary wedge pressure (PCWP) via a pulmonary artery catheter. Laboratory monitoring includes electrolytes (particularly potassium), blood glucose, and renal function. For dobutamine stress echocardiography, continuous echocardiographic wall motion monitoring is mandatory throughout the procedure.
Dobutamine should not be given to pregnant women unless the expected clinical benefit clearly outweighs the potential risk to the fetus. There is very limited data on the use of dobutamine in human pregnancy. In practice, dobutamine may be used during pregnancy in life-threatening situations such as cardiogenic shock or peripartum cardiomyopathy, where the benefit of maintaining maternal hemodynamic stability justifies the theoretical risks. The decision must be made on a case-by-case basis by the treating medical team, and the lowest effective dose should be used for the shortest possible duration.
Tolerance to the hemodynamic effects of dobutamine can develop after approximately 72 hours of continuous infusion. This is thought to be due to downregulation of beta-1 adrenergic receptors on cardiac myocytes. When tolerance occurs, higher doses may be required to maintain the same level of hemodynamic support. Management strategies include dose escalation, intermittent rather than continuous infusion (drug holidays), or switching to an alternative inotropic agent such as milrinone (a phosphodiesterase III inhibitor), which acts through a different mechanism and does not rely on adrenergic receptor stimulation.
References
This article is based on the following peer-reviewed sources and international guidelines:
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- Overgaard CB, Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118(10):1047-1056. doi:10.1161/CIRCULATIONAHA.107.728840
- Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease. Journal of the American Society of Echocardiography. 2020;33(1):1-41.e8. doi:10.1016/j.echo.2019.07.001
- British National Formulary (BNF). Dobutamine. NICE Evidence Services. Updated 2024.
- European Medicines Agency (EMA). Summary of Product Characteristics – Dobutamine-containing medicinal products. EMA/CHMP. Accessed January 2026.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, consisting of specialist physicians in cardiology, critical care medicine, and clinical pharmacology. All content follows the GRADE evidence framework and adheres to international guidelines from the ESC, AHA, and WHO.
iMedic Medical Editorial Team — Specialists in Cardiology and Clinical Pharmacology
iMedic Medical Review Board — Independent expert panel reviewing content according to international standards
Level 1A — Based on systematic reviews, meta-analyses, and randomized controlled trials
None. Independent medical content with no pharmaceutical company sponsorship or commercial funding.